Application Note

MEA to probe ALS phenotypes in neuronal disease models

Explore an MEA workflow used to validate the ALS-relevant phenotype of precision reprogrammed iPSC-derived neuronal disease models of ALS from bit.bio

Early-stage ALS drug discovery workflows can be challenging due to a lack of access to consistent, physiologically relevant human cell models. In this app note, discover a functional iPSC-derived neuronal model of ALS from bit.bio. Also, explore an MEA workflow featuring the Axion Maestro Pro that was used to validate this model’s reduced neuronal activity and network formation compared to a genetically matched control, highlighting its physiological relevance for pre-clinical ALS research.